Compare ZYME & NEOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZYME | NEOG |
|---|---|---|
| Founded | 2003 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2022 | 1995 |
| Metric | ZYME | NEOG |
|---|---|---|
| Price | $24.96 | $9.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $38.90 | $10.67 |
| AVG Volume (30 Days) | 548.3K | ★ 2.2M |
| Earning Date | 05-07-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | $105,965,000.00 | ★ $894,661,000.00 |
| Revenue This Year | $183.10 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $459.25 |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $11.02 | $4.53 |
| 52 Week High | $29.75 | $11.43 |
| Indicator | ZYME | NEOG |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 54.42 |
| Support Level | $24.79 | $8.98 |
| Resistance Level | $27.54 | $10.12 |
| Average True Range (ATR) | 1.23 | 0.38 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 34.35 | 85.32 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.